Blunt Business reflects the ongoing congressional gridlock of federal legalization efforts and the need for more voices to reach a larger public to counteract the constant attacks made by lobbying efforts and the negative media coverage. We also look forward to the pending DEA schedule change and what it will bring to the industry in 2024.
Sponsored by The Buzz CRM
Brought to you by The Buzz CRM
The Buzz CRM proudly sponsors this show.
Enjoy this episode?
Subscribe to Blunt Business for new episodes.
More from Blunt Business
A Psychedelic and Cannabis Research Revolution On the Horizon?
Blunt Business
This episode of Blunt Business explores a significant shift in federal drug policy following a new executive order aimed at accelerating research into psychedelics like LSD, psilocybin, and ibogaine for treating mental health disorders.